The Minimal Clinically Important Difference for the "Patient Activation Measure".

Area of Science:

• Nephrology
• Health Psychology
• Clinical Research

Background:

• Patient activation, crucial for self-managing health, is often measured by the Patient Activation Measure (PAM-13) in chronic kidney disease (CKD).
• Interpreting the clinical significance of changes in patient-reported outcomes like PAM-13 requires understanding the minimal clinically important difference (MCID).

Purpose of the Study:

• To establish the MCID and minimal detectable change (MDC) for the PAM-13 in patients with nondialysis CKD.
• To provide benchmarks for interpreting the clinical meaningfulness of PAM-13 score changes in this population.

Main Methods:

• Retrospective secondary analysis of a randomized control trial in a nondialysis CKD population.
• MCID estimation using anchor-based (Short Form-12 survey) and distribution-based methods.
• MDC calculation for assessing absolute reliability at individual and group levels.

Main Results:

• The study included 136 participants with nondialysis CKD (mean eGFR: 37.3 ml/min/1.73 m²).
• The estimated MCID for PAM-13 was 5.4 points (95% CI: 3.4-7.4).
• The minimal detectable change (MDC) was 7.2 points at the individual level (MDC_indv) and 0.8 points at the group level (MDC_group).

Conclusions:

• The established MCID and MDC values for PAM-13 offer crucial benchmarks for researchers and clinicians.
• These findings facilitate a better interpretation of patient-reported outcome improvements from the patient's perspective in CKD care.
• This research aids in determining the clinical meaningfulness of changes in patient activation for individuals with CKD.